A430033K04Rik Activators encompass a range of chemical compounds that engage with various cellular signaling pathways to amplify the functional activity of A430033K04Rik. Forskolin, by augmenting intracellular cAMP levels, can boost A430033K04Rik activity through PKA-dependent mechanisms, assuming A430033K04Rik's involvement in such cAMP-responsive pathways. Similarly, Genistein and Epigallocatechin gallate (EGCG) could enhance A430033K04Rik's function by attenuating competitive kinase signaling, potentially shifting the balance towards A430033K04Rik-associated pathways. Glucokinase activators are compounds that either directly enhance the enzyme's substrate processing or indirectly influence its activity through modulation of related metabolic pathways. Glucose, as the primary substrate, directly promotes Glucokinase activity, with increased glucose levels resulting in a higher rate of glucose-6-phosphate production. Additionally, ATP serves as a phosphate donor in the Glucokinase reaction, while Magnesium ions are crucial for ATP's structural stability when interacting with Glucokinase, both contributing to heightened enzyme activity. A430033K04Rik Activators denote a class of chemicals that can stimulate the expression of the A430033K04Rik gene.
To identify compounds that can act as activators, researchers utilize a high-throughput screening (HTS) strategy. This technique leverages a reporter gene assay, a system in which a reporter gene-typically encoding a readily measurable product like a fluorescent or luminescent protein-is placed under the control of the A430033K04Rik gene promoter. When a diverse array of chemical substances is introduced to a cellular system containing this reporter construct, activator compounds can be identified by an increase in the reporter's signal, indicating promoter activation. This increase in signal directly correlates to the compound's ability to enhance the activity of the A430033K04Rik promoter. Compounds that result in a significant elevation in signal are then selected for more detailed examination to verify their role as activators of the A430033K04Rik gene.
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG inhibits several protein kinases, altering signaling pathways such as the MAPK pathway, which could lead to the activation of A430033K04Rik if it is implicated in these pathways. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
S1P binds to its G-protein-coupled receptors, influencing downstream signaling pathways that can enhance A430033K04Rik function if it is coupled to these lipid signaling pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that by reducing PI3K/Akt signaling can indirectly activate A430033K04Rik by shifting the balance towards pathways that A430033K04Rik is involved in. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 inhibits MEK, which may lead to the activation of A430033K04Rik by modulating the MAPK/ERK pathway if A430033K04Rik is associated with this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, which can enhance A430033K04Rik function by altering the p38 MAPK signaling pathway that A430033K04Rik may participate in. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin disrupts calcium homeostasis, potentially enhancing A430033K04Rik activity through the activation of calcium-dependent signaling if linked to A430033K04Rik's function. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Although a broad-spectrum kinase inhibitor, Staurosporine could selectively enhance A430033K04Rik signaling pathways by inhibiting kinases that negatively regulate pathways associated with A430033K04Rik. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates PKC, which may lead to the enhancement of A430033K04Rik by modulating signaling pathways that involve diacylglycerol and protein kinase C, if A430033K04Rik is part of these pathways. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, potentially enhancing A430033K04Rik activity by activating calcium-dependent proteins and pathways associated with A430033K04Rik's function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that could indirectly activate A430033K04Rik by shifting cell signaling dynamics away from PI3K/Akt pathway to pathways in which A430033K04Rik is involved. |